Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Epidemiology/Health Services/Psychosocial Research

Prevalence of Insulin Resistance Syndrome in Southwestern France and Its Relationship With Inflammatory and Hemostatic Markers

  1. Pedro Marques-Vidal, MD, PHD1,
  2. Elizabeth Mazoyer, MD2,
  3. Vanina Bongard, MD1,
  4. Pierre Gourdy, MD3,
  5. Jean-Bernard Ruidavets, MD1,
  6. Ludovic Drouet, MD, PHD2 and
  7. Jean Ferrières, MD, MSC, FESC1
  1. 1INSERM U558, Faculté de Médecine Purpan, Toulouse, France
  2. 2Service d’Angio-Hématologie Biologique et Moléculaire, Hôpital Lariboisière, Paris, France
  3. 3Service de Diabétologie, Maladies Métaboliques et Nutrition, C.H.U. Rangueil, Toulouse, France
    Diabetes Care 2002 Aug; 25(8): 1371-1377. https://doi.org/10.2337/diacare.25.8.1371
    PreviousNext
    • Article
    • Figures & Tables
    • Info & Metrics
    • PDF
    Loading

    Abstract

    OBJECTIVE—To assess the prevalence and relationships of insulin resistance syndrome (IRS) with inflammatory and hemostatic markers in a representative sample of the population of Southwestern France aged 35–64 years.

    RESEARCH DESIGN AND METHODS—In this cross-sectional study, data were collected from 597 men and 556 women and were assessed regarding BMI, blood pressure, total and HDL cholesterol levels, triglyceride level, glucose level, plasma insulin level, white blood cell count, fibrinogen level, factor VII level, von Willebrand factor, C-reactive protein level, soluble intercellular adhesion molecule, soluble vascular cell adhesion molecule-1, and soluble CD14. Insulin resistance was defined by homeostasis model assessment ≥3.8.

    RESULTS—Prevalence of IRS was higher in men than in women (23 vs. 12%, respectively; P < 0.001) and increased with age in both sexes (9, 24, and 34% for age groups 35–44, 45–54, and 55–64 years, respectively, for men and 4, 10, and 21% for women). After adjusting for age, alcohol consumption, tobacco smoking, and also for menopause in women, subjects (men and women) with IRS had significantly higher white blood cell count, factor VII levels, coagulating factor VII levels, and C-reactive protein levels than the other subjects. In men, further increases in soluble intercellular adhesion molecule and soluble vascular cell adhesion molecule-1 were noted, whereas in women, the differences were borderline significant. Conversely, no differences were found in fibrinogen, von Willebrand factor, and soluble CD14 in both sexes.

    CONCLUSIONS—IRS is relatively common in residents of Southwestern France and is related to a deleterious increase in hemostatic and inflammatory parameters.

    • CRP, C-reactive protein
    • DBP, diastolic blood pressure
    • FPG, fasting plasma glucose
    • FVIIa, activated factor VII
    • FVIIc, factor VII coagulant
    • HOMA, homeostasis model assessment
    • IFG, impaired fasting glucose
    • IRS, insulin resistance syndrome
    • SBP, systolic blood pressure
    • sCD14, soluble CD14
    • sICAM, soluble intercellular adhesion molecule
    • sVCAM-1, soluble vascular cell adhesion molecule-1
    • WHR, waist-to-hip ratio

    Insulin resistance syndrome (IRS) is characterized by the clustering of several cardiovascular risk factors, such as increased insulin levels, hypertension, obesity, and dyslipidemia (1), and is related to an increased cardiovascular risk (2) and an increased incidence of coronary heart disease (3). Although the effects of IRS on atherosclerosis and coronary heart disease are believed to be exerted via the different risk factors that compose this clinical entity (4), less is known regarding the levels of inflammatory, hemostatic, and endothelial cell activation (5). Furthermore, although the prevalence of IRS has been assessed in several populations (6–9), only very few studies have focused on its prevalence in France. Therefore, we used data from the third MONICA survey to assess the prevalence of IRS and the levels of inflammatory and hemostatic factors in patients of both sexes with IRS in Southwestern France, a region characterized by a low level of cardiovascular disease (10).

    RESEARCH DESIGN AND METHODS

    Populations

    The World Health Organization MONICA Project is a study that monitors deaths due to coronary heart disease and myocardial infarction, coronary care, and risk factors in men and women aged 35–64 years (11). It consists of 39 MONICA Collaborative Centers in 26 countries. Each MONICA Collaborative Center is in charge of performing two or three population surveys on cardiovascular risk factors in the beginning and at the end of the 10th year and possibly in the middle of the study period. The sampling strategy was to have representative probability samples within each sex and 10-year age group, at least for subjects aged 35–64 years. The number of eligible subjects asked to participate was 50% higher than the required number to obtain the necessary quota of 200 persons for each sex and 10-year age group (allowing for subjects refusing to participate or not participating for any other reason). The survey was conducted in Southwestern France (Department of Haute-Garonne, with a population of ∼360,000 subjects aged 35–64 years) between December 1994 and July 1997 and included subjects of both sexes. Polling lists available in each town hall and a list of foreigners living in the survey area were used for sampling. Informed consent to participate in the study was obtained from the subjects before the survey. Participation rates were 67 and 59% for men and women, respectively.

    Data collection

    Subjects were advised to refrain from physical exercise, smoking, eating, and drinking anything other than water for at least 10 h before the screening visit (12). Screening included standardized questionnaires on personal data and clinical measurements. Height and weight were measured according to a standardized protocol (12); BMI was assessed as kg/m2. Professional activity was based on current status (employed/unemployed/sick leave/retired), and educational level was based on the number of years spent in school/university. Women were also questioned about use of oral contraceptives. Subjects were considered current smokers if they answered yes to the question “do you currently smoke cigarettes?”. Subjects were considered drinkers if they reported drinking any amount of alcohol during the week.

    Alcohol consumption was assessed by a questionnaire on which the subject reported his mean consumption (in units) of wine, beer, cider, and spirits for each day of the week. Intake of alcohol (expressed in milliliters of pure ethanol/week) was estimated from the average number of milliliters of ethanol in a serving of each type of alcoholic beverage and multiplying by 0.8 (density of ethanol): wine, 12-cl serving, 10 or 12% alcohol (vol/vol); beer, 12-cl serving, 5% alcohol; beer, 25- or 33-cl serving, 6 or 8% alcohol; cider, 12-cl serving, 5% alcohol; spirits, 2- or 6-cl serving, 20% or 40% alcohol.

    Blood pressure measurement

    Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured twice on the right arm of subjects who had been resting for at least 5 min in a comfortable position. Two consecutive measurements of SBP and DBP were recorded to the nearest 2 mmHg, and the mean values of these were used for the present analysis. Hypertension was defined as SBP ≥140 mmHg and/or DBP ≥90 mmHg and/or presence of antihypertensive treatment.

    Biological measurements

    Lipids were measured on plasma EDTA plasma samples using automated enzymatic assays (Boehringer, Mannheim, Germany). External quality control by the MONICA reference laboratory indicated no relevant deviation. Non-HDL cholesterol was calculated as the difference between total cholesterol and HDL cholesterol.

    Glucose levels were measured by the glucose oxidase method (Du Pont Dimension; Du Pont, Wilmington, DE). Total plasma insulin was measured by radioimmunoassay (BiInsuline, Eria Pasteur, France). Previously diagnosed diabetes was defined by current oral hypoglycemic treatment and newly diagnosed diabetes was defined as fasting plasma glucose (FPG) ≥7.0 mmol/l. Impaired fasting glucose (IFG) was defined by 6.1 ≤ FPG ≤ 6.9 mmol/l (13). Insulin resistance was estimated by the homeostasis model assessment (HOMA) defined as fasting serum insulin (μU/ml) × FPG (mmol/l)/22.5. Subjects with HOMA ≥3.8 (lower level of the population upper quartile) were considered insulin resistant.

    Fibrinogen was assessed by the method of Clauss using an automated device (Diagnostica Stago, Asnières, France). Factor VII coagulant (FVIIc) was assessed by chronometric assay (Diagnostica Stago), and the results were expressed as percentage of a standardized pool of normal subjects. Activated factor VII (FVIIa) was assessed by a chronometric assay with a recombinant tissue factor (Statclot-rTF; Diagnostica Stago), and results were expressed in mU/ml. Assessment of both FVIIc and FVIIa was performed on the same automated device (STA; Diagnostica Stago). von Willebrand factor activity levels were assessed using a platelet aggregation technique on a BCT (Behring coagulation timer) device (Dade Behring Marburg, Marburg, Germany). C-reactive protein (CRP) levels were assessed by immunonephelemetric method (Dade Behring Marburg); the lower limit of detection was 0.175 mg/l. Levels of soluble vascular cell adhesion molecule-1 (sVCAM-1) and soluble intercellular adhesion molecule (sICAM) were assessed by immunoenzymatic methods (Immunotech, Marseilles, France). Levels of soluble CD14 (sCD14) were assessed by immunoenzymatic methods (IBL, Hamburg, Germany). Between-series coefficients of variation (maximum values) were as follows: fibrinogen 3.6%, FVIIc 5.3%, von Willebrand factor 8%, CRP 4.4%, sCD14 11%, sVCAM-1 8.7%, and sICAM 6.9%.

    IRS

    Presence of IRS was determined by HOMA ≥3.8 and/or presence of antidiabetic drug treatment and/or fasting blood glucose ≥6.1 mmol/l, as well as at least two of the following conditions (14): 1) anthropometrical data: BMI ≥30 kg/m2 or a waist-to-hip ratio (WHR) ≥0.95 (for men) or ≥0.85 (for women); 2) blood pressure: SBP >140 mmHg or DBP >90 mmHg or presence of antihypertensive treatment; 3) dyslipidemia: triglyceride level >1.70 mmol/l or HDL level <0.90 mmol/l or presence of triglyceride-lowering drug therapy.

    Statistical analysis

    Subjects on insulin therapy (two men, one woman) or subjects who had fasted <10 h (15 men, 12 women) were excluded from the analysis. Statistical analysis was conducted using SAS statistical software (version 8.1; SAS Institute, Cary, NC). Quantitative data were expressed as mean ± SD or as adjusted mean ± SE; qualitative data were expressed as number of subjects and percentage. Univariate comparisons were performed using χ2 or Student’s t test; multivariate adjustments were performed using a generalized linear model (Proc GLM; SAS Institute) or by stepwise multiple linear regression. Significance was established for P < 0.05.

    RESULTS

    Subject characteristics

    Overall, data from 1,153 subjects were assessed (597 men and 556 women). Their clinical characteristics are summarized in Table 1. BMI, WHR, blood pressure levels, total cholesterol and triglyceride levels, HOMA, insulin, white blood cell count, sICAM, and sVCAM-1 were lower and HDL cholesterol, fibrinogen, FVIIc, and von Willebrand factor levels were higher in women than in men, whereas no differences were found regarding age, FPG level, FVIIa, CRP, and sCD14. Also, prevalence of ex-smokers, IFG, and diabetes (diagnosed + FPG ≥7.0 mmol/l) was higher in men.

    Prevalence of insulin resistance

    The prevalence of the main components of IRS is shown in Table 2. Prevalence of WHR, hypertension, hypertriglyceridemia, low HDL cholesterol, dyslipidemia, and insulin resistance (defined by a HOMA ≥3.8 or antidiabetic treatment) was higher in men than in women, whereas no differences were found regarding obesity or antihypertriglyceridemic, antihypertensive, or antidiabetic drug therapy (Table 2). Prevalence of IRS was higher in men than in women (Table 2), but this difference decreased with increasing age. Prevalence of IRS also increased with age in both sexes: in men, prevalence of IRS was 9, 24, and 34% for age groups 35–44, 45–54, and 55–64 years, respectively (P < 0.001); in women, the corresponding values were 4, 10, and 21% (P < 0.001).

    Levels of inflammatory and hemostatic parameters in insulin-resistant patients

    For each sex, the levels of inflammatory and hemostatic parameters were assessed between IRS and non-IRS subjects, after adjusting for age group (three groups), drinking status (yes/no), and smoking status (yes/no). In women, a further adjustment on menopausal status was performed. Results are summarized in Table 3. In both men and women, subjects with IRS had significantly higher white blood cell count and levels of FVIIa, FVIIc, and CRP than the other subjects (Table 3). In men, further significant increases in sICAM and sVCAM were noted; the corresponding increases in women were borderline significant (P < 0.07). Conversely, no differences were found for fibrinogen, von Willebrand factor, and sCD14 in both men and women.

    Relationships between IRS components and inflammation and coagulation biomarkers

    The relationships were assessed independently for men and women, by stepwise multiple regression, using each inflammatory and coagulation marker as a dependent variable and age, alcohol consumption, smoking, BMI, WHR, HOMA, HDL and non-HDL cholesterol, triglycerides (as Log), and blood pressure as independent variables. The results are expressed in Tables 4 and 5. In men, age, smoking, WHR, HOMA, HDL cholesterol, and triglycerides were related to most of the inflammatory and coagulation markers, whereas in women, the most important determinants were age, BMI, and triglycerides. Furthermore, significant sex/covariate interactions were found for several inflammatory and hemostatic markers, namely age (for FVIIa, FVIIc, CRP, and sCD14), alcohol consumption (for fibrinogen and sCD14), smoking (for white blood cell count and fibrinogen), and triglycerides (for fibrinogen, FVIIc, and CRP). Finally, when HOMA was replaced by insulin and plasma glucose, only insulin was selected for all variables tested (not shown).

    CONCLUSIONS

    Most studies using factor analysis to characterize insulin resistance led to similar results, i.e., that three to four main factors could be drawn: a factor related to anthropometrical data, another related to blood pressure, and another related to lipid values. However, a factor related to insulin levels has not been consistently found (3, 15,16). In this study and to allow for further comparisons, we chose to define IRS according to the World Health Organization recommendations (1,14). Furthermore, although its reliability among older obese subjects has been questioned (17), HOMA provides a useful model to assess insulin resistance and β-cell function in epidemiological studies in which only fasting samples are available (18). It is also a reliable marker of insulin resistance for assessment and follow-up of patients with diabetes (19). In this study, we chose to use the lower limit of the upper quartile of the HOMA distribution in the overall population to define insulin resistance.

    The main objective of this study was to assess the prevalence of IRS in the general population of Southwestern France (20). Therefore, subjects who were treated for hypertension, hypertriglyceridemia, or diabetes were not excluded from the analysis, because this would create a selection bias leading to an underestimation of the true prevalence of IRS in this population. Indeed, excluding treated subjects from the analysis led to a much lower prevalence of IRS (12% in men and 4% in women), because a considerable number of subjects were treated for hypertension, hypertriglyceridemia, or diabetes. Furthermore, it should be stressed that most studies focusing on the metabolic interrelationships of IRS did not indicate whether treated subjects were excluded from the statistical analysis (15). Notwithstanding, our data indicate that excluding subjects with treated cardiovascular risk factors leads to a considerable underestimation of the true prevalence of IRS in the general population and might also bias the metabolic interrelationships, although this latter hypothesis deserves further investigation.

    The prevalence of IRS reported in this study was much higher than that in studies of Mexicans (6) and native Americans (21) but was in relative agreement with another study conducted in Caucasians (22). Possible explanations for this discrepancy are the fact that the authors of one of the studies (6) did not include obesity in their definition of IRS, as well as differences regarding nutritional intake, physical activity, and socioeconomic status. However, our data indicate that prevalence of IRS in the population of Southwestern France is high and increases with age.

    Subjects with IRS had significantly higher levels of CRP, an inflammatory marker that has been shown to be predictive of cardiovascular disease (23). Those findings are in agreement with previously published studies (5), and although the increase in CRP levels among patients with IRS might be due to obesity or high insulin levels (24), our data suggest that part of the cardiovascular effect of insulin resistance might be mediated by inflammation. This hypothesis is further confirmed by an increase in white blood cell count in patients with IRS. Conversely, no differences were found for fibrinogen between IRS and non-IRS subjects, although significant relationships were found between fibrinogen levels and age, alcohol consumption, smoking, HDL, and triglycerides, in agreement with previous findings (25). A possible explanation for this result is the intricate and differential relationships between fibrinogen levels and components of IRS; for instance, fibrinogen levels are positively related to BMI but negatively related to WHR.

    sICAM and sVCAM are molecular markers for endothelial cell activation, arteriosclerosis, and development of coronary heart disease (26). In this study, both sICAM and sVCAM-1 levels were significantly increased in men with IRS, with borderline significant differences in women. Those findings were further confirmed by the fact that IRS parameters explained ∼10% of the overall variation of sICAM, whereas their effect in variation of sVCAM-1 was much lower (Tables 4 and 5). von Willebrand factor is also synthesized by endothelial cells, and its increased plasma level is usually considered a marker for endothelial lesion (27) and predictive of cardiovascular mortality in diabetic and nondiabetic subjects (28). Conversely, in this study, no increase in von Willebrand factor was noted with IRS, contrary to other studies conducted in patients with type 2 diabetes (29). Also, in both men and women, most of the IRS parameters explained only a small part of the total variance of von Willebrand factor levels, further confirming the lack of relationship between IRS and von Willebrand factor. Still, our findings indicate a possible association between IRS and increased endothelial cell activation, namely mediated by sICAM and sVCAM levels, which could also mediate the development of atherosclerosis and coronary heart disease in this group.

    FVIIa is produced after activation of FVII by tissue factor and is a marker of the activation status of this tissue factor coagulation pathway when detected in vivo; increased levels of FVIIc also have been shown to be a risk factor for coronary heart disease (30). In this study, increased FVIIc and FVIIa levels were found in both men and women with IRS, indicating a possible procoagulant status associated with IRS. Those findings are in agreement with previously published studies (5) and indicate that the increased levels of FVII might partly be due to several components of IRS, such as increased BMI (31), lipid levels (25), or insulin resistance (32). Therefore, our data indicate that the relationship between IRS, atherosclerosis, and coronary heart disease might be more complex than initially believed because of IRS exerting its effects not only through its components (insulin resistance, obesity, high blood pressure, and dyslipidemia) but also via several other metabolic pathways such as inflammation, coagulation, or endothelial cell activation (33).

    The association of CD14 with bacterial lipopolysaccharide stimulates endothelial and smooth muscle cells, and some polymorphisms of CD14, have been associated with myocardial infarction (34). Nevertheless, in this study, no increase in the levels of sCD14 was found in patients with IRS. Therefore, according to our data, it seems unlikely that IRS exerts its effects through a modification of sCD14 levels.

    Stepwise multiple regression showed that age, BMI, WHR, HDL cholesterol, and triglycerides were the IRS components that were most frequently related with the hemostatic, inflammatory, and endothelial cell markers studied. Notwithstanding, the magnitude of the effect of each IRS component differed between sexes: in men, it was WHR (not BMI) and HDL cholesterol (not triglycerides) that were significantly related to the inflammatory and hemostatic variables, whereas in women, it was BMI (not WHR) and mostly triglycerides. Those findings were further confirmed by the assessment of significant interactions between sex and triglycerides in relationship with hemostatic, inflammatory, and endothelial cell markers. Therefore, our data indicate that the effect of at least one of the components of the IRS (triglycerides) differs according to sex.

    The mechanisms by which insulin resistance influences hemostatic, inflammatory, and endothelial cell activation are complex and multiple, with the specific effect of insulin on selected gene polymorphisms (35,36) or via other metabolic pathways such as BMI or lipid levels (32). In this study, HOMA and insulin levels were frequently associated with hemostatic, inflammatory, and endothelial cell markers in men but not in women and, contrary to findings of other authors (37), no significant interactions were found between sex and HOMA levels regarding those markers. A possible explanation is the higher prevalence of increased HOMA levels and IRS in men (Table 2), which would lead to stronger relationships in men than in women. Notwithstanding, further research is needed to assess the differential metabolic relationships between IRS and hemostatic, inflammatory, and endothelial cell markers in men and women.

    In summary, our data indicate that the prevalence of IRS is relatively high in middle-aged subjects living in Southwestern France. Our data also indicate that this clinical status is related to increases in several hemostatic, inflammatory, and endothelial cell markers and that those increases seem to differ according to sex.

    View this table:
    • View inline
    • View popup
    Table 1—

    Characteristics of the subjects, by sex

    View this table:
    • View inline
    • View popup
    Table 2—

    Presence of the main components of the insulin resistance syndrome, by sex

    View this table:
    • View inline
    • View popup
    Table 3—

    Inflammatory and hemostatic parameters in subjects with and without IRS, by sex

    View this table:
    • View inline
    • View popup
    Table 4—

    Relationships between hemostatic and inflammatory markers and components of IRS men

    View this table:
    • View inline
    • View popup
    Table 5—

    Relationships between hemostatic and inflammatory markers and components of IRS in women

    Acknowledgments

    We thank all the investigators of the Toulouse MONICA center for their invaluable contribution in the careful collection and validation of the data.

    Footnotes

    • Address correspondence and reprint requests to Jean Ferrières, INSERM U558, Faculté de Médecine, Département d’ Epidémiologie, 1er étage, 37, Allées Jules Guesde, 31073 Toulouse cedex, France. E-mail: ferriere{at}cict.fr.

      Received for publication 15 October 2001 and accepted in revised form 20 April 2002.

      A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

    • DIABETES CARE

    References

    1. ↵
      Groop L, Orho-Melander M: The dysmetabolic syndrome. J Intern Med 250: 105–120, 2001
      OpenUrlCrossRefPubMedWeb of Science
    2. ↵
      Bao W, Srinivasan SR, Berenson GS: Persistent elevation of plasma insulin levels is associated with increased cardiovascular risk in children and young adults: the Bogalusa Heart Study. Circulation 93:54–59, 1996
      OpenUrlAbstract/FREE Full Text
    3. ↵
      Lempiainen P, Mykkanen L, Pyorälä K, Laakso M, Kuusisto J: Insulin resistance syndrome predicts coronary heart disease events in elderly nondiabetic men. Circulation 100:123–128, 1999
      OpenUrlAbstract/FREE Full Text
    4. ↵
      Lindblad U, Langer RD, Wingard DL, Thomas RG, Barrett-Connor EL: Metabolic syndrome and ischemic heart disease in elderly men and women. Am J Epidemiol 153:481–489, 2001
      OpenUrlAbstract/FREE Full Text
    5. ↵
      Sakkinen PA, Wahl P, Cushman M, Lewis MR, Tracy RP: Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol 152:897–907, 2000
      OpenUrlAbstract/FREE Full Text
    6. ↵
      Gonzalez Villalpando C, Stern MP, Haffner S, Arredondo Perez B, Martinez Diaz S, Islas Andrade S: The insulin resistance syndrome in Mexico: prevalence and clinical characteristics: a population based study. Arch Med Res 26:S9–S15, 1995
    7. Zamora-Gonzalez J, Yamamoto-Kimura L, Lerman-Garber I, Cardoso-Saldana G, Fajardo-Gutierrez A, Posadas-Romero C: Clustering of metabolic disorders and hyperinsulinemia in Mexico City. Int J Obes Relat Metab Disord 20:311–318, 1996
      OpenUrlPubMedWeb of Science
    8. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, Alberiche M, Bonadonna RC, Muggeo M: Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes 47:1643–1649, 1998
      OpenUrlAbstract
    9. ↵
      Lindeman RD, Romero LJ, Hundley R, Allen AS, Liang HC, Baumgartner RN, Koehler KM, Schade DS, Garry PJ: Prevalences of type 2 diabetes, the insulin resistance syndrome, and coronary heart disease in an elderly, biethnic population. Diabetes Care 21:959–966, 1998
      OpenUrlAbstract/FREE Full Text
    10. ↵
      Ferrières J, Amouyel P, Arveiler D, Cambou JP, Ruidavets JB, Bingham A, Richard JL: The MONICA project: trends in coronary disease frequency and severity in France. In Omega-3, Lipoproteins and Atherosclerosis. Davignon J, Fruchart JC, Ordovas JM, Eds. Paris, John Libbey Eurotext, 1996, p.1–5
    11. ↵
      WHO MONICA Project Principal Investigators, prepared by Tunstall-Pedoe H: The World Health Organization MONICA Project (MONItoring trends and determinants in CArdiovascular disease): a major international collaboration. J Clin Epidemiol 41:105–114, 1988
      OpenUrlCrossRefPubMedWeb of Science
    12. ↵
      WHO MONICA Project: MONICA Manual. Geneva, World Health Org., 1990
    13. ↵
      Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20:1183–1197, 1997
      OpenUrlFREE Full Text
    14. ↵
      WHO: Definition, Diagnosis and Classification of Diabetes Mellitus. Geneva, World Health Org., 1999
    15. ↵
      Edwards KL, Austin MA, Newman B, Mayer E, Krauss RM, Selby JV: Multivariate analysis of the insulin resistance syndrome in women. Arterioscler Thromb 14:1940–1945, 1994
      OpenUrlAbstract/FREE Full Text
    16. ↵
      Meigs JB, D’Agostino RB, Wilson PW, Cupples LA, Nathan DM, Singer DE: Risk variable clustering in the insulin resistance syndrome: the Framingham Offspring Study. Diabetes 46:1594–1600, 1997
      OpenUrlAbstract/FREE Full Text
    17. ↵
      Ferrara CM, Goldberg AP: Limited value of the homeostasis model assessment to predict insulin resistance in older men with impaired glucose tolerance. Diabetes Care 24:245–249, 2001
      OpenUrlAbstract/FREE Full Text
    18. ↵
      Hermans MP, Levy JC, Morris RJ, Turner RC: Comparison of insulin sensitivity tests across a range of glucose tolerance from normal to diabetes. Diabetologia 42:678–687, 1999
      OpenUrlCrossRefPubMedWeb of Science
    19. ↵
      Katsuki A, Sumida Y, Gabazza EC, Murashima S, Furuta M, Araki-Sasaki R, Hori Y, Yano Y, Adachi Y: Homeostasis model assessment is a reliable indicator of insulin resistance during follow-up of patients with type 2 diabetes. Diabetes Care 24:362–365, 2001
      OpenUrlAbstract/FREE Full Text
    20. ↵
      Gourdy P, Ruidavets J, Ferrières J, Ducimetière P, Amouyel P, Arveiler D, Cottel D, Lamamy N, Bingham A, Hanaire-Broutin H: Prevalence of type 2 diabetes and impaired fasting glucose in the middle-aged population of three French regions: the MONICA study 1995–97. Diabete Metab 27:347–358, 2001
      OpenUrlPubMed
    21. ↵
      Greenlund KJ, Valdez R, Casper ML, Rith-Najarian S, Croft JB: Prevalence and correlates of the insulin resistance syndrome among Native Americans: the Inter-Tribal Heart Project. Diabetes Care 22:441–447, 1999
      OpenUrlAbstract
    22. ↵
      Beck-Nielsen H: General characteristics of the insulin resistance syndrome: prevalence and heritability: the European Group for the study of Insulin Resistance (EGIR). Drugs 58:7–10, 1999
      OpenUrl
    23. ↵
      Strandberg TE, Tilvis RS: C-reactive protein, cardiovascular risk factors, and mortality in a prospective study in the elderly. Arterioscler Thromb Vasc Biol 20:1057–1060, 2000
      OpenUrlAbstract/FREE Full Text
    24. ↵
      Hak AE, Stehouwer CD, Bots ML, Polderman KH, Schalkwijk CG, Westendorp IC, Hofman A, Witteman JC: Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler Thromb Vasc Biol 19:1986–1991, 1999
      OpenUrlAbstract/FREE Full Text
    25. ↵
      Scarabin PY, Aillaud MF, Amouyel P, Evans A, Luc G, Ferrières J, Arveiler D, Juhan-Vague I: Associations of fibrinogen, factor VII and PAI-1 with baseline findings among 10,500 male participants in a prospective study of myocardial infarction-the PRIME Study: Prospective Epidemiological Study of Myocardial Infarction. Thromb Haemost 80:749–756, 1998
      OpenUrlPubMedWeb of Science
    26. ↵
      Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342:836–843, 2000
      OpenUrlCrossRefPubMedWeb of Science
    27. ↵
      Richard S, Seigneur M, Blann A, Adams R, Renard M, Puntous M, Boiron JM, Amiral J, Reiffers J, Boisseau M: Vascular endothelial lesion in patients undergoing bone marrow transplantation. Bone Marrow Transplant 18:955–959, 1996
      OpenUrlPubMedWeb of Science
    28. ↵
      Jager A, van Hinsbergh VW, Kostense PJ, Emeis JJ, Yudkin JS, Nijpels G, Dekker JM, Heine RJ, Bouter LM, Stehouwer CD: von Willebrand factor, C-reactive protein, and 5-year: mortality in diabetic and nondiabetic subjects: the Hoorn Study. Arterioscler Thromb Vasc Biol 19:3071–3078, 1999
      OpenUrlAbstract/FREE Full Text
    29. ↵
      Heywood DM, Mansfield MW, Grant PJ: Levels of von Willebrand factor, insulin resistance syndrome, and a common vWF gene polymorphism in non-insulin-dependent (type 2) diabetes mellitus. Diabet Med 13:720–725, 1996
      OpenUrlCrossRefPubMedWeb of Science
    30. ↵
      Junker R, Heinrich J, Schulte H, van de Loo J, Assmann G: Coagulation factor VII and the risk of coronary heart disease in healthy men. Arterioscler Thromb Vasc Biol 17:1539–1544, 1997
      OpenUrlAbstract/FREE Full Text
    31. ↵
      Balleisen L, Bailey J, Epping PH, Schulte H, van de Loo J: Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population: I. Baseline data on the relation to age, gender, body-weight, smoking, alcohol, pill-using, and menopause. Thromb Haemost 54:475–479, 1985
      OpenUrlPubMedWeb of Science
    32. ↵
      Cushman M, Yanez D, Psaty BM, Fried LP, Heiss G, Lee M, Polak JF, Savage PJ, Tracy RP: Association of fibrinogen and coagulation factors VII and VIII with cardiovascular risk factors in the elderly: the Cardiovascular Health Study. Am J Epidemiol 143:665–676, 1996
      OpenUrlAbstract/FREE Full Text
    33. ↵
      Festa A, D’Agostino R, Howard G, Mykkanen L, Tracy RP, Haffner SM: Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102:42–47, 2000
      OpenUrlAbstract/FREE Full Text
    34. ↵
      Unkelbach K, Gardemann A, Kostrzewa M, Philipp M, Tillmanns H, Haberbosch W: A new promoter polymorphism in the gene of lipopolysaccharide receptor CD14 is associated with expired myocardial infarction in patients with low atherosclerotic risk profile. Arterioscler Thromb Vasc Biol 19:932–938, 1999
      OpenUrlAbstract/FREE Full Text
    35. ↵
      Niessen RW, Pfaffendorf BA, Sturk A, Lamping RJ, Schaap MC, Hack CE, Peters M: The influence of insulin, beta-estradiol, dexamethasone and thyroid hormone on the secretion of coagulant and anticoagulant proteins by HepG2 cells. Thromb Haemost 74:686–692, 1995
      OpenUrlPubMedWeb of Science
    36. ↵
      Heywood DM, Mansfield MW, Grant PJ: Factor VII gene polymorphisms, factor VII:C levels and features of insulin resistance in non-insulin-dependent diabetes mellitus. Thromb Haemost 75:401–406, 1996
      OpenUrlPubMedWeb of Science
    37. ↵
      Mennen LI, Balkau B, Charles MA, D’Hour A, le Mauff JM: Gender differences in the relation between fibrinogen, tissue-type plasminogen activator antigen and markers of insulin resistance: effects of smoking. D.E.S.I.R. Study Group: Data from an epidemiological study on insulin resistance syndrome. Thromb Haemost 82:1106–1111, 1999
      OpenUrlPubMedWeb of Science
    PreviousNext
    Back to top
    Diabetes Care: 25 (8)

    In this Issue

    August 2002, 25(8)
    • Table of Contents
    • About the Cover
    • Index by Author
    Sign up to receive current issue alerts
    View Selected Citations (0)
    Print
    Download PDF
    Article Alerts
    Sign In to Email Alerts with your Email Address
    Email Article

    Thank you for your interest in spreading the word about Diabetes Care.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Prevalence of Insulin Resistance Syndrome in Southwestern France and Its Relationship With Inflammatory and Hemostatic Markers
    (Your Name) has forwarded a page to you from Diabetes Care
    (Your Name) thought you would like to see this page from the Diabetes Care web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Citation Tools
    Prevalence of Insulin Resistance Syndrome in Southwestern France and Its Relationship With Inflammatory and Hemostatic Markers
    Pedro Marques-Vidal, Elizabeth Mazoyer, Vanina Bongard, Pierre Gourdy, Jean-Bernard Ruidavets, Ludovic Drouet, Jean Ferrières
    Diabetes Care Aug 2002, 25 (8) 1371-1377; DOI: 10.2337/diacare.25.8.1371

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    Add to Selected Citations
    Share

    Prevalence of Insulin Resistance Syndrome in Southwestern France and Its Relationship With Inflammatory and Hemostatic Markers
    Pedro Marques-Vidal, Elizabeth Mazoyer, Vanina Bongard, Pierre Gourdy, Jean-Bernard Ruidavets, Ludovic Drouet, Jean Ferrières
    Diabetes Care Aug 2002, 25 (8) 1371-1377; DOI: 10.2337/diacare.25.8.1371
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Jump to section

    • Article
      • Abstract
      • RESEARCH DESIGN AND METHODS
      • RESULTS
      • CONCLUSIONS
      • Acknowledgments
      • Footnotes
      • References
    • Figures & Tables
    • Info & Metrics
    • PDF

    Related Articles

    Cited By...

    More in this TOC Section

    • Suboptimal Use of Cardioprotective Drugs in Newly Treated Elderly Individuals With Type 2 Diabetes
    • Disparities in Diabetes Care Between Smokers and Nonsmokers
    • Elevated Cystatin C Concentration and Progression to Pre-Diabetes
    Show more Epidemiology/Health Services/Psychosocial Research

    Similar Articles

    Navigate

    • Current Issue
    • Standards of Care Guidelines
    • Online Ahead of Print
    • Archives
    • Submit
    • Subscribe
    • Email Alerts
    • RSS Feeds

    More Information

    • About the Journal
    • Instructions for Authors
    • Journal Policies
    • Reprints and Permissions
    • Advertising
    • Privacy Policy: ADA Journals
    • Copyright Notice/Public Access Policy
    • Contact Us

    Other ADA Resources

    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • Scientific Sessions Abstracts
    • Standards of Medical Care in Diabetes
    • BMJ Open - Diabetes Research & Care
    • Professional Books
    • Diabetes Forecast

     

    • DiabetesJournals.org
    • Diabetes Core Update
    • ADA's DiabetesPro
    • ADA Member Directory
    • Diabetes.org

    © 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.